乌干达三地监测显示抗疟药耐药模式变化
研究评估了2012、2013和2015年乌干达三个地点收集的恶性疟原虫耐药标志物。与氨基喹啉类耐药相关但增加鲁美凡特灵敏感性的假定转运蛋白突变(pfcrt 76T;pfmdr1 86Y和1246Y)在所有地点显著下降。抗叶酸耐药突变常见,与高水平耐药相关的突变(pfdhfr 164L;pfdhps 581G)似乎出现。与青蒿素耐药相关的K13突变不常见且未随时间增加。
要点
- 乌干达三地恶性疟原虫pfcrt 76T及pfmdr1 86Y/1246Y突变频率显著下降。
- 抗叶酸耐药突变普遍,pfdhfr 164L和pfdhps 581G似有新出现。
- K13青蒿素耐药突变少见且未随时间增加。
核心结论
- 疟疾治疗实践的改变伴随着耐药标志物的深刻变化。
研究设计与样本
- 在乌干达三个地点于2012、2013和2015年收集恶性疟原虫并评估耐药标志物。
主要发现
- pfcrt 76T及pfmdr1 86Y和1246Y突变频率在所有地点显著下降。
- 抗叶酸耐药突变常见,pfdhfr 164L和pfdhps 581G似有新出现。
- K13突变不常见且未随时间增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We assessed Plasmodium falciparum drug resistance markers in parasites collected in 2012, 2013, and 2015 at 3 sites in Uganda. The prevalence and frequency of parasites with mutations in putative transporters previously associated with resistance to aminoquinolines, but increased sensitivity to lumefantrine (pfcrt 76T; pfmdr1 86Y and 1246Y), decreased markedly at all sites. Antifolate resistance mutations were common, with apparent emergence of mutations (pfdhfr 164L; pfdhps 581G) associated with high-level resistance. K13 mutations linked to artemisinin resistance were uncommon and did not increase over time. Changing malaria treatment practices have been accompanied by profound changes in markers of resistance.
引用
- Tumwebaze P, Tukwasibwe S, Taylor A, et al. Changing Antimalarial Drug Resistance Patterns Identified by Surveillance at Three Sites in Uganda. J Infect Dis. 2017. PMID: 28039354. doi:10.1093/infdis/jiw614
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。